TAVR-MET: Early Signs Point to Less Postprocedural Valve Dysfunction With Tirzepatide Patients with obesity randomized to the drug had less subclinical leaflet thrombosis and paravalvular leak than controls.

Patients with obesity who are on tirzepatide before undergoing TAVI may be at lower risk of developing subclinical leaflet thrombosis and paravalvular leaks, according to the small, randomized TAVR-MET trial. More here: www.tctmd.com/news/tavr-me...
#CRT2026

SOLVE-TAVI: Patient Sex, for the Most Part, Doesn’t Sway Outcomes by Valve Type Women had better self-care at 5 years with self-expanding valves, raising questions about lower gradients and stroke impacts.

Men and women with severe aortic stenosis and intermediate-to-high surgical risk have similar long-term outcomes after TAVI whether they receive a self-expanding or balloon-expandable valve, based on 5-year analysis of the SOLVE-TAVI trial. More here: www.tctmd.com/news/solve-t...
#CRT2026

Large Variability in Use of Invasive Strategy for Type 1 NSTEMI: NCDR The sickest patients are more likely to be managed conservatively, despite what the guidelines say.

A large majority of patients with type 1 NSTEMI undergo invasive coronary angiography in the US, with most receiving PCI. However, there is significant variability in the management approach across different sites, according to a new study analysis. www.tctmd.com/news/large-v...
#CRT2026

AGENT IDE Midterm Results Still Give DCB an Edge for In-Stent Restenosis At 3 years, Agent still outshined uncoated balloons. Registry data show rapid uptake of the DCB in the year after its FDA approval.

The Agent drug-coated balloon continues to hold an advantage over uncoated balloon angioplasty alone in high-risk patients with in-stent restenosis, according to a new 3-year follow-up data from AGENT IDE. More here: www.tctmd.com/news/agent-i...
#CRT2026

DOBERMANN: Dobutamine and Tocilizumab Show Promise in Pre-Shock Patients While the strategies didn’t lower NT-proBNP after PCI in acute MI patients, they may suggest a way forward for intervening early.

Two trials, the DOBERMANN-D and DOBERMANN-T, show possible promising effects of inotropic therapy and a monoclonal antibody in high-risk acute MI patients, even though they fell short of lowering NT-proBNP after PCI, their primary endpoints. Read more here: www.tctmd.com/news/doberma...
#CRT2026

Huge thanks to the CRT organizers for an incredible #CRT2026! 🙌 The focus on coronary microvascular disease & women’s cardiovascular health sparked vital discussions and connections. Grateful for the collaboration! 💙 #InterventionalCardiology #CMD #WomensHeartHealth

#CRT2026

#CRT2026

#CRT2026

What a memorable #CRT2026! Thank you to the IC community for the meaningful conversations and shared passion for advancing interventional cardiology forward.

The future is bright. We can’t wait to see you at #CRT2027!

A strong finish to #CRT2026.

Grateful to be in Washington, D.C., for CRT & to have the opportunity to participate in a CardioTube interview Dr. R. Caputo & Dr. D. Cox, discussing advancements in radial closure.

Thoughtful dialogue. Real-world insights. Meaningful connections.

@CRT_meeting

On March 9th, President Joseph R. Biden
gave the keynote address at #CRT2026

Clip from IG, he was just a little bit heated about what the monster in the White House is doing.

crtmeeting.org/program/keyn...

DOBERMANN: Dobutamine and Tocilizumab Show Promise in Pre-Shock Patients While the strategies didn’t lower NT-proBNP after PCI in acute MI patients, they may suggest a way forward for intervening early.

www.tctmd.com/news/doberma... #CardioSky #CRT2026

Defining Exercise Hemodynamics and Function After Transcatheter Aortic Valve Replacement: The DEFINE-TAVR Prospective Study Transcatheter aortic valve replacement (TAVR) has transformed the treatment of severe aortic stenosis; however, up to 20% to 30% of patients continue to experience symptoms that limit quality of life ...

📢🆕Defining Exercise Hemodynamics & Function After #TAVR: The DEFINE-TAVR Prospective Study provides the first prospective evaluation of TAVR valve performance during exercise.

📖 jscai.org/article/S277...

🎙️Presented at #CRT2026 today!

#TranscatheterAorticValveReplacement #Echocardiogram #JSCAI

Just in from #CRT2026: Results from the pharmacokinetic study show that AGENT™ DCB’s paclitaxel drug delivers superior drug retention to Selution SLR™ DEB’s sirolimus drug, with AGENT’s drug retention out to 120 days.

Learn more about AGENT DCB: qrco.de/bger64

CRT 2026: What to Expect in Washington, DC Amid late-breaking coronary, structural, and endovascular trials will be a keynote from President Biden, and more.

The CRT conference starts tomorrow in Washington, DC! Get a preview of what to expect, from late-breaking trials to a keynote from former President Biden. More here: www.tctmd.com/news/crt-202...
#CRT2026

Excited for CRT 2026! Join us in DC to discuss the future of coronary physiology and diagnostic insights. Let’s connect! #CRT2026 #FFR #CoronaryPhysiology #InterventionalCardiology #CardiologyInnovation

Join us at #CRT2026

Join us at #CRT2026 to see AGENT™ DCB and Selution SLR™ under the microscope showing before and after simulated catheter tracking. Visit Boston Scientific’s Tech Suite to explore drug coating durability prior to inflation and why drug loss before treatment matters.

📍 See you at #CRT2026 We look forward to connecting & being part of the largest interventional cardiology meeting on the East Coast.

📅 March 7–10
📍 Washington Hilton Hotel

Interventionalists: Your community. Your conference. Let’s go.

#InterventionalCardiology #RadialAccess #MedTech

See our Next Gen Tech Suite at CRT 2026!

Are you attending #CRT2026? Come check out our interactive Next Gen Tech Suite! Showing you how we are advancing patient care and what’s next in cardiology.

Learn more: qrco.de/bgdoAy

Join Boston Scientific at #CRT2026

Join Boston Scientific at #CRT2026 and dive into the future of cardiology. Explore our lineup of can’t-miss symposia and meet the experts sessions to see how we are advancing patient care and driving innovation.

See the schedule: qrco.de/bgdoAy

💼 Calling all interventional cardiologists! Only 1 week left to RSVP for SCAI’s Capitol Hill Advocacy Day at #CRT2026. Make an impact on health policy and funding priorities that matter most.

Learn more and join us in Washington, DC on March 9➡️ https://ow.ly/i07150Y93zE

#SCAIAdvocacy #CardioSky

Registro celular: La nueva huella digital obligatoria en México Tu línea móvil ya no es anónima. Vinculación CURP-INE es obligatoria antes del 30/06/2026. Conecta o queda desconectado.

Tu línea móvil ya no es anónima. Vinculación CURP-INE es obligatoria antes del 30/06/2026. Conecta o queda desconectado.
#RegistroCelular #VinculaTuLinea #CRT2026